Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-28T00:48:13.511Z Has data issue: false hasContentIssue false

EPA-0255 – Clinical Relevance of as-Needed Treatment with Nalmefene in Alcohol Dependent Patients

Published online by Cambridge University Press:  15 April 2020

H. Aubin
Affiliation:
Psychiatry and Addiction Science Department, Univerité Hospital Paul Brousse, Villejuif, France
J. Reimer
Affiliation:
Centre for Interdisciplinary Addiction Research, Hamburg University, Hamburg, Germany
D. Nutt
Affiliation:
Department of Medicine, Imperial College, London, United Kingdom
L. Torup
Affiliation:
Addictive Behaviors, H. Lundbeck A/S, Valby, Denmark
C. François
Affiliation:
Pharmacoeconomics, H. Lundbeck A/S, Issy les Moulineaux, France
J. Chick
Affiliation:
Health Sciences, Queen Margaret University, Edinburgh, United Kingdom

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction:

The opioid system modulator nalmefeneis the first pharmacological therapy approved in the European Union for reduction of alcohol consumption.

Objectives:

To evaluate the clinical relevance of the reduction of alcohol consumption in patients with at least high drinking risk level at screening and randomisation from the two, identically designed, randomised controlled 6-month studies ESENSE1 (NCT00811720) and ESENSE2 (NCT00812461) of nalmefene versus placebo.

Methods:

Study medication was taken as-needed. All patients received a motivational and adherence-enhancing intervention (BRENDA). Response criteria were based on alcohol consumption at month 6 and Clinical Global Impression – Severity of Illness/Improvement (CGI-S/I), Short Form Health Survey version 2 (SF-36) mental component summary(MCS) scores at week 24. Clinical relevance was also studied using the Drinker Inventory of Consequences (DrInC), Alcohol Dependence Scale (ADS), and liver function variables.

Results:

Pooled study population: 667 patients (placebo N=332; nalmefene N=335). The proportion of responders was higher in the nalmefene group than in the placebo group with odds ratios for response consistently significantly (p<0.05) in favour of nalmefene. The difference in the proportions of responders translated to numbers-needed-to-treat ranging from 6 to 10. Significant differences to placebo (p<0.05) in the SF-36 MCS and physical component summary score, ADS, DrInC, CGI-I/S and liver enzymes further supported the clinical relevance of the treatment effect.

Conclusions:

In view of the immense alcohol-related burden to society, the harm to the individual and the large treatment gap partly due to a reluctance to engage in abstinence, the effect of nalmefene is clearly clinically relevant.

Type
E03 – e-Poster Oral Session 03: Addiction and Geriatric Psychiatry
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.